

Special Issue

Basic Virological Aspects of SARS-CoV-2

Message from the Guest Editors

This new information required about SARS-CoV-2 needed to be focused on understanding the physiopathology of the COVID-19 disease, identifying biomarkers, and designing a vaccine and treatments. The scope of this Special Issue is to gather information about the basic virology aspects of SARS-CoV-2 and their impact on the design of vaccines and/or drugs. Further, the basic virology aspect can be focused on to understand the physiopathology of COVID-19 disease. Before the COVID-19 pandemic, SARS viruses had a relative slow evolution rate. However, globalization, unequal strategies to control or mitigate the pandemic around the world, and the generation of several vaccines increased the evolution rate. This evolution, centered in the scape of the immune system, had a great impact on the persistence of the pandemic and a critical decrease in vaccines' effectiveness. Therefore, understanding the basic virological aspect of this virus through high-quality information will allow us to generate better strategies against this virus.

Guest Editors

Dr. Andreu Comas-Garcia
Dr. Sofia Bernal-Silva
Prof. Dr. S. Louise Cosby

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/151004

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).